Merck's earnings transcript reveals a resilient performance in the face of challenges. The inability to sustain VYTORIN/ZETIA sales due to the ENHANCE trial outcomes is a concern, leading to a reduction in guidance for these drugs' impact on 2008 equity income. However, strong performances by other products, particularly GARDASIL, JANUVIA and ISENTRESS, along with cost-cutting measures and a leaner manufacturing network, position the company well. The management's resolve to navigate through виз uncertainties and focus on diversifying their portfolio is encouraging. Despite the disruptions, Merck reaffirms its 2010 goals, boosting confidence. 

[0]